Evidence map›Paper›PMID 28543019›Full record

ArticleAllergy2017

The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU.

M Maurer, M Abuzakouk, F Bérard, W Canonica, H Oude Elberink, A Giménez-Arnau, C Grattan, K Hollis, A Knulst, J-P Lacour and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 168 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
168citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

168 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

108 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

M MaurerCharité - Universitätsmedizin Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0002-4121-481X
M AbuzakoukCleveland Clinic Abu Dhabi, Abu Dhabi, UAE.
F BérardClaude Bernard University Lyon, Lyon, France.
W CanonicaIRCCS-Humanitas Research Hospital, Humanitas University, Rozzano-Milano, Italy.
H Oude ElberinkUniversity of Groningen, Groningen, The Netherlands.
A Giménez-ArnauHospital del Mar, Universitat Autònoma, Barcelona, Spain.
C GrattanGuy's Hospital, London, UK.
K HollisRTI Health Solutions, Research Triangle Park, NC, USA.
A KnulstUniversity Medical Center Utrecht, Utrecht, The Netherlands.
J-P LacourUniversité Nice Sophia Antipolis, Nice, France.
C LyndeLynderm Research, Toronto, ON, Canada.
A MarslandSalford Royal Hospital, University of Manchester, Salford, UK.
D McBrideRTI Health Solutions, Manchester, UK.
A NakonechnaRoyal Liverpool and Broadgreen University Hospitals, Liverpool, UK.
J Ortiz de FrutosHospital 12 Octubre, Madrid, Spain.
C ProctorRTI Health Solutions, Research Triangle Park, NC, USA.
G SussmanUniversity of Toronto, Toronto, ON, Canada.
C SweeneyRTI Health Solutions, Research Triangle Park, NC, USA.
H TianNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
K WellerCharité - Universitätsmedizin Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0003-4437-0313
D WolinRTI Health Solutions, Research Triangle Park, NC, USA.
M-M BalpNovartis Pharma AG, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic spontaneous urticaria (CSU) can be debilitating, difficult to treat, and frustrating for patients and physicians. Real-world evidence for the burden of CSU is limited. The objective of this study was to document disease duration, treatment history, and disease activity, as well as impact on health-related quality of life (HRQoL) and work among patients with inadequately controlled CSU, and to describe its humanistic, societal, and economic burden.

methodsThis international observational study assessed a cohort of 673 adult patients with CSU whose symptoms persisted for ≥12 months despite treatment. Demographics, disease characteristics, and healthcare resource use in the previous 12 months were collected from medical records. Patient-reported data on urticaria and angioedema symptoms, HRQoL, and work productivity and activity impairment were collected from a survey and a diary.

resultsAlmost 50% of patients had moderate-to-severe disease activity as reported by Urticaria Activity Score. Mean (SD) Dermatology Life Quality Index and Chronic Urticaria Quality of Life Questionnaire scores were 9.1 (6.62) and 33.6 (20.99), respectively. Chronic spontaneous urticaria markedly interfered with sleep and daily activities. Angioedema in the previous 12 months was reported by 66% of enrolled patients and significantly affected HRQoL. More than 20% of patients reported ≥1 hour per week of missed work; productivity impairment was 27%. These effects increased with increasing disease activity. Significant healthcare resources and costs were incurred to treat CSU.

conclusionsChronic spontaneous urticaria has considerable humanistic and economic impacts. Patients with greater disease activity and with angioedema experience greater HRQoL impairments.

Indexed as

Cost of IllnessActivities of Daily LivingAdultAgedAged, 80 and overChronic DiseaseCross-Sectional StudiesFemaleGuideline AdherenceHealth Care CostsHealth SurveysHumansMaleMiddle AgedQuality of LifeSleepangioedemaeconomic burdenobservational studyquality of lifeurticaria

Identifiers

PMID28543019
PMCPMC5724512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.